
    
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by
      participating institution.

      Patients are randomly assigned to 1 of 3 groups: low-dose intravenous mucoid
      exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IVIG), high-dose MEP IVIG, or
      placebo. Therapy is administered every 28 days for 12 months. Treatment is not initiated in
      the presence of an acute asthmatic attack.

      Concurrent chronic suppressive antibiotics are permitted.
    
  